Biogen, the biggest Massachusetts-based biotechnology company, said Tuesday that it plans to sell a manufacturing plant in Denmark to Fujifilm for about $890 million as the Japanese company seeks to strengthen its health care business.
The approximately 800 Biogen employees at the plant in Hillerød, Denmark, are expected to continue working under Fujifilm. Fujifilm plans to sign a manufacturing services agreement with Biogen and will use the facility to make products for the drug company, including Tysabri, Biogen’s blockbuster medicine for multiple sclerosis.
Michel Vounatsos, Biogen’s chief executive, said the Cambridge biotech plans to open a state-of-the-art manufacturing facility by the end of next year in Solothurn, Switzerland, and no longer needs the Danish plant.
“Fujifilm is a well-respected leader in manufacturing biologic products, and they share our pioneering culture,” he said.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
The deal with Fujifilm, which has built a contract manufacturing business for drug makers as its photography and imaging operations have shrunk, is expected to close in the second half of this year.
Biogen also has a manufacturing plant in Research Triangle Park in North Carolina.
Date: March 18, 2019
Source: Bostonglobe
